About Us
MISSION
We are discovering new drug targets, nutraceuticals and botanical drugs that prevent the aging-related metabolic diseases.
Obesity
Obesity has been regarded as a complex consequence that results from metabolic, hormonal and cellular disorders. We discovered a pivotal obesity gene, a cytosolic NADP+-dependent isocitrate dehydrogenase that plays a key role in lipid metabolism (J Biol Chem 279: 39968). This finding facilitated our research to find potential therapeutics that effectively reduce body fat and further to develop a novel botanical extract, Actiponin®.
Inflammation
Inflammation is a biological process that involves the interaction of various types of cells and molecules. In particular, chronic inflammation is associated with aging-related cellular and metabolic diseases, such as cancer and arthritis. The molecular and cellular mechanism of inflammation proceeds five phases and involves a complex network of signaling pathways. Some of the key signaling pathways include NF- κB, cytokines, AMPK, MAPK, JAK, STAT, and others. Because Actiponin® activates AMPK it is most probable that Actiponin® modulates the immunological processes that are under the control of AMPK. We are committted to search for novel nutraceuticals and botanical drugs as well as elements of Actiponin®, which demonstrate robust anti-inflammatory potentials.
Excercise Endurance
Exercise endurance can be defined as the ability to sustain prolonged physical activity. Molecular and cellular processes of exercise endurance are largely associated with multiple adaptations in skeletal muscle. We thus focus on two critical elements that characterize exercise endurance associated with skeletal muscle. First, mitochondrial biogenesis increases the number and size of mitochondria in skeletal muscle, consequently enhancing the capability of skeletal muscle cells to produce more of energy (ATP) aerobically for more prolonged exercise endurance. Second, capacity of skeletal muscle to metabolize fatty acids determines levels of exercise endurance. Using the two characteristics, we are screening nutraceuticals and botanical drugs which improve exercise endurance.
MANAGEMENT
CEO & Founder
Dr. Tae-Lin Huh is developing TG Biotech that he founded in 2000 into Korea’s leading nutraceuticals and botanical drug company. His research and development have been focused on biological metabolisms and signaling pathways at molecular levels over 35 years, as a visiting associate and scientist at NIH, USA and a professor at Kyungpook National University, Republic of Korea. During the periods, he discovered the novel molecular targets including the ever-first reported obesity gene. In 2009, Dr. Huh developed Actiponin®, the first in class nutraceuticals for the treatments of obesity. He is currently investigating molecular components of Actiponin® as well as new nutraceuticals that control the aging-related metabolic diseases. He expects details of novel networks of Actiponin® and others open up new ground for treatment of chronic inflammation, exercise endurance, and aging-related metabolic diseases.
Values
Openness; We believe that openness among the members of TG Biotech as well as diverse global research institutes enhances our research and development to discover essential nutraceuticals and botanical drugs which prevent aging-related metabolic diseases.
Integrity; We believe that integrity of individuals as well as teams of TG Biotech ensure scientific proofs and highest quality of our products.
Safety & Efficacy; We believe that our openness together with integrity creates environment to generate safe nutraceuticals and botanical drugs. Every TG Biotech product will highlight us as one of the most innovative company.
CHRONICLES
Major Shareholders
♦ Dong-A ST
♦ The Korea Development Bank (KDB) Capital
♦ SeouLin Bioscience Co. Ltd.
♦ Korea Investment Management Co. Ltd.
♦ Yuamco Helios Small and Medium Business Growth Startup Venture – Specialized Private Equity Joint Venture
Actiponin®
♦ Actiponin® is a trademark of the standardized Gynostemma pentaphyllum leaf extract.
♦ Actiponin® has been distributed in Korea, Japan and other Asian countries by TG Biotech. In the USA, the distribution agency of Actiponin® is CellMark USA.
♦ Actiponin® was approved as a Health Functional Food Functional Raw Material (Certification No. 2013-8) by the Korea Mistry of Food and Drug Safety.
♦ Actiponin® was approved as a New Dietary Ingredient (NDI) by US Food and Drug Administration (May 12, 2023).
